via bloomberg.com
The deal includes two Amylin drugs, pramlintide/metreleptin and davalintide, in Phase 2 of testing needed for U.S. regulatory approval.
Takeda will pay 80 percent of costs linked with U.S. Food and Drug Administration marketing approval and all of the development costs of obtaining clearance for approval of products outside the U.S.
1 comment:
Wow, that's a fat payout! ;-)
Post a Comment